Status: Recruiting
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
Phase 2 Study of TYRA-300 in FGFR3 Altered Low Grade, Intermediate Risk NMIBC
Participants needed: 90
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Tyra Biosciences, IncUpdated: Sep 29, 2026Locations: 48
Eligibility criteria
Participants age ≥18 at time of informed consent and willing and able to comply... [+21]
Current or previous history of muscle invasive bladder cancer [+23]